JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target

Benzinga · 2d ago
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.